Compare Alphabet Inc Class A (GOOGL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Pfizer Inc — how do they compare? Alphabet Inc Class A trades at $350.72 (market cap $4.24T), while Pfizer Inc trades at $28.06 (market cap $158.56B). The key difference: Alphabet Inc Class A is far larger — about 26.7× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and Pfizer Inc for 158 Days on average.
| GOOGL | PFE | |
|---|---|---|
Market Cap | $4.24T | $158.56B |
Volume | 23,392,850 | 44,138,282 |
Sector | Media | Health |
52-Week High | $402.62 | $29.02 |
52-Week Low | $236.59 | $23.67 |
Typical Hold Time | 85 Days | 158 Days |
Enterprise Value | $4.13T | $210.06B |
Dividend Yield | 0.25% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GOOGL trades at $350.50, up 0.81% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional financial performance with 2025 revenue of $402.84B and net income of $132.17B, achieving consistent earnings beats. Recent news highlights AI-driven growth opportunities through partnerships with Anthropic and SpaceX, while YouTube's subscription price increases signal revenue diversification. Analyst consensus remains overwhelmingly positive with 87% buy ratings.
Outlook remains favorable given strong fundamentals and AI leadership, though regulatory risks and market volatility present challenges. The $431.83 consensus price target implies 23% upside potential. Investment opportunity centers on sustained AI monetization and cloud growth, balanced against antitrust scrutiny and competitive pressures in digital advertising.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
